Cargando…
Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991541/ https://www.ncbi.nlm.nih.gov/pubmed/36896213 http://dx.doi.org/10.1016/j.adro.2023.101179 |
_version_ | 1784902173511909376 |
---|---|
author | Eckstein, Jacob Gogineni, Emile Sidiqi, Baho Lisser, Noah Parashar, Bhupesh |
author_facet | Eckstein, Jacob Gogineni, Emile Sidiqi, Baho Lisser, Noah Parashar, Bhupesh |
author_sort | Eckstein, Jacob |
collection | PubMed |
description | PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local control (LC), overall survival (OS), and toxicity when treating spine metastases. METHODS AND MATERIALS: All patients at our institution who received spine SBRT from 2010 to 2019 with systemic therapy data available were reviewed retrospectively. The primary endpoint was LC. Secondary endpoints were toxicity (fracture and radiation myelitis) and OS. Kaplan-Meier analysis was used to determine whether IT sequencing (before versus after SBRT) and use of IT were associated with LC or OS. RESULTS: A total of 191 lesions in 128 patients met inclusion criteria with 50 (26%) lesions in 33 (26%) patients who received IT. Fourteen (11%) patients with 24 (13%) lesions received the first IT dose before SBRT, whereas 19 (15%) patients with 26 (14%) lesions received the first dose after SBRT. LC did not differ between lesions treated with IT before SBRT versus after SBRT (1 year 73% versus 81%, log rank = 0.275, P = .600). Fracture risk was not associated with IT timing (χ(2) = 0.137, P = .934) or receipt of IT (χ(2) = 0.508, P = .476), and no radiation myelitis events occurred. Median OS was 31.8 versus 6.6 months for the IT after SBRT versus IT before SBRT cohorts, respectively (log rank = 13.193, P < .001). On Cox univariate analysis and multivariate analysis, receipt of IT before SBRT and Karnofsky performance status <80 were associated with worse OS. IT treatment versus none was not associated with any difference in LC (log rank = 1.063, P = .303) or OS (log rank = 1.736, P = .188). CONCLUSIONS: Sequencing of IT and SBRT was not associated with any difference in LC or toxicity, but delivering IT after SBRT versus before SBRT was associated with improved OS. |
format | Online Article Text |
id | pubmed-9991541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99915412023-03-08 Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases Eckstein, Jacob Gogineni, Emile Sidiqi, Baho Lisser, Noah Parashar, Bhupesh Adv Radiat Oncol Scientific Article PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local control (LC), overall survival (OS), and toxicity when treating spine metastases. METHODS AND MATERIALS: All patients at our institution who received spine SBRT from 2010 to 2019 with systemic therapy data available were reviewed retrospectively. The primary endpoint was LC. Secondary endpoints were toxicity (fracture and radiation myelitis) and OS. Kaplan-Meier analysis was used to determine whether IT sequencing (before versus after SBRT) and use of IT were associated with LC or OS. RESULTS: A total of 191 lesions in 128 patients met inclusion criteria with 50 (26%) lesions in 33 (26%) patients who received IT. Fourteen (11%) patients with 24 (13%) lesions received the first IT dose before SBRT, whereas 19 (15%) patients with 26 (14%) lesions received the first dose after SBRT. LC did not differ between lesions treated with IT before SBRT versus after SBRT (1 year 73% versus 81%, log rank = 0.275, P = .600). Fracture risk was not associated with IT timing (χ(2) = 0.137, P = .934) or receipt of IT (χ(2) = 0.508, P = .476), and no radiation myelitis events occurred. Median OS was 31.8 versus 6.6 months for the IT after SBRT versus IT before SBRT cohorts, respectively (log rank = 13.193, P < .001). On Cox univariate analysis and multivariate analysis, receipt of IT before SBRT and Karnofsky performance status <80 were associated with worse OS. IT treatment versus none was not associated with any difference in LC (log rank = 1.063, P = .303) or OS (log rank = 1.736, P = .188). CONCLUSIONS: Sequencing of IT and SBRT was not associated with any difference in LC or toxicity, but delivering IT after SBRT versus before SBRT was associated with improved OS. Elsevier 2023-01-16 /pmc/articles/PMC9991541/ /pubmed/36896213 http://dx.doi.org/10.1016/j.adro.2023.101179 Text en © 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Eckstein, Jacob Gogineni, Emile Sidiqi, Baho Lisser, Noah Parashar, Bhupesh Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title | Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title_full | Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title_fullStr | Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title_full_unstemmed | Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title_short | Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases |
title_sort | effect of immunotherapy and stereotactic body radiation therapy sequencing on local control and survival in patients with spine metastases |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991541/ https://www.ncbi.nlm.nih.gov/pubmed/36896213 http://dx.doi.org/10.1016/j.adro.2023.101179 |
work_keys_str_mv | AT ecksteinjacob effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases AT gogineniemile effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases AT sidiqibaho effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases AT lissernoah effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases AT parasharbhupesh effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases |